Inactive Instrument

Midatech Pharma PLC Stock Nasdaq

Equities

US59564R1041

Biotechnology & Medical Research

Financials

Sales 2024 * - Sales 2025 * - Capitalization 4.63M 5.8M 7.96M
Net income 2024 * - Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 57.92%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
European Equities Close Higher in Friday Trading; Anglo American Rejects BHP Takeover Bid MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% MT
Biodexa Pharmaceuticals Gets Exclusive License for Phase 3 Ready Drug to Treat Familial Adenomatous Polyposis -- Shares Jump MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rebound in Monday Trading MT
Biodexa Pharmaceuticals Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading MT
More news
Managers TitleAgeSince
Chief Executive Officer 62 19-09-08
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer 44 21-07-10
Members of the board TitleAgeSince
Chairman 65 22-06-19
Director/Board Member 65 14-10-28
Chief Executive Officer 62 19-09-08
More insiders
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
More about the company